Jupiter Neurosciences Inc(JUNS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:50 PM ET (Korea 9/12 08:50)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -19.11 | Insider Own | 43.04% | Shs Outstand | 1.3M | Perf Week | -6.44% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.8M | Perf Month | -33.84% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 2.25% | Short Float | 7.58% | Perf Quarter | -82.24% |
| Income | -0.01B | P/S | 66.97 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.06 | Perf Half Y | -88.96% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -239.36% | Short Interest | 0.06M | Perf YTD | -96.01% |
| Book/sh | -0.55 | P/C | 2.64 | EPS past 3/5Y | -18.3% -7.78% | ROE | -1888.7% | 52W High | -97.79% ($137.96) | Perf Year | -97.39% |
| Cash/sh | 1.15 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 5.9% ($2.88) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -43.11% | Gross Margin | 81.8% | Volatility(W/M) | 9.28% 17.36% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 71.3 | Sales Y/Y TTM | - | Oper. Margin | -15166.68% | ATR (14) | 0.83 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.62 | EPS Q/Q | 19.9% | Profit Margin | -14220.12% | RSI (14) | 27.47 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.66 | Sales Q/Q | - | SMA20 | -28.9% ($4.29) | Beta | 1.72 | Target Price | $1875 |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -61.34% ($7.89) | Rel Volume | 0.02 | Prev Close | $3.15 |
| Employees | 5 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -91.17% ($34.54) | Avg Volume(3M) | 0.98M | Price | $3.05 |
| IPO | 2024/12/3 | Option/Short | No/Yes | Trades | 221 | Volume | 20,858 | Change | -3.17% |
Company
JUNS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧠 Jupiter Neurosciences is a clinical-stage biotech company targeting central nervous system (CNS) disorders with JOTROL™, its patented micellar delivery platform for resveratrol. The company highlights over 9x higher bioavailability compared to conventional resveratrol and is expanding into rare CNS indications such as Parkinson's disease, Alzheimer's, Friedreich's ataxia, and MELAS. Using the same technology, it also operates the Nugevia™ nutraceutical brand.
Over the past 1 year, on the lower side
98% below its 1-year high.
JUNS has weak earning power
Review management risk carefully before investing
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Generally in line with estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 2.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $4M.
JUNS $4M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is JUNS?
JUNS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of JUNS?
The market cap of JUNS is approximately $4M, ranking 5,736 within its sector.
What is the 52-week high and low for JUNS?
JUNS has recorded a 52-week high of $137.96 and a low of $2.88.
